Lauromacrogol Sclerotherapy

The therapeutic effect follows a linked vascular response rather than a single event. Lauromacrogol first disrupts the endothelial lining, the cells covering the inside of the vessel. Vasoconstriction narrows the treated vessel, while thrombus formation and subsequent fibrosis reinforce closure. Together, these changes produce durable occlusion of the targeted channel.

Vasoconstriction and thrombus formation reinforce the initial endothelial injury by narrowing the lumen and adding an obstructive clot. Fibrosis then provides a later structural response that maintains occlusion. This sequence matters because it describes how the treated vessel progresses from an acute response to a fibrotically closed channel rather than relying on narrowing or clotting alone.

Closing the treated vessel can reduce venous reflux, meaning backward venous flow, when the unwanted channel contributes to that problem. The intervention therefore targets a flow abnormality as well as a visible vessel. Its clinical value is not limited to appearance, because occlusion can alter circulation through the treated venous pathway.

Ultrasound guidance helps clinicians identify the vessel and improve placement of the injection within the intended vascular channel. This is particularly relevant when the target is not adequately represented by surface appearance alone. More accurate delivery supports treatment of the selected vessel while helping clinicians monitor for unintended vascular injury, a recognized complication.

Clinicians may administer lauromacrogol as either a liquid or foam. The available information identifies both as delivery forms but does not establish that one is universally preferable. Recognizing these alternatives helps describe the procedure accurately while keeping formulation within broader clinical planning that includes the target vessel, patient selection, and guidance strategy.

In medicine, the principal application is treatment of varicose veins, with selected venous malformations representing another use. Appropriate patient selection matters because the technique is not presented as suitable for every vascular abnormality. When the target is appropriate, treatment may reduce venous reflux and visible vessels without surgical removal.

Monitoring remains important after injection because local and vascular responses can produce unwanted effects. Reported concerns include inflammation and pigmentation, as well as unintended vascular injury. Follow-up allows clinicians to assess the treated area and identify these complications rather than assuming that vessel closure alone guarantees an uncomplicated result.